MAIA (48) ACRV (38) CING (36) TELO (34) ⌘ Pro Terminal →

Lifevantage Corporation (Delaware) (LFVN) — RQD Stock Rating Cockpit

$5.88 +0.17% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.90

Lifevantage Corporation (Delaware) (LFVN) earns a Roarable Rating of B+ (Buy) with 76/100 RQD Confidence. High-quality cash engine (80% profit margin, 29% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 76/100 (B+) historically ranked in the Top 11% of excess returns over the next 90 days (+7.6% avg 90D alpha vs SPY • 70.0% hit rate) →

ROARABLE B+ • BUY Cap $73.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LFVN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LFVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Lifevantage Corporation (Delaware) (NASDAQ: LFVN) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $5.88 (+0.17% 1D, market cap $73.9M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 19/20. Across 1016 tracked Health Care issuers, LFVN ranks #34 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LFVN compare to MAIA and ACRV in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LFVN carries a Roarable B+ (76/100 RQD), trailing P/E of 7.5x, gross margin of 80.4%, and ROIC of 29.2%. By comparison, MAIA (MAIA Biotechnology Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $72.9M) and ACRV (Acrivon Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $75.4M). Among the 5-stock peer group, LFVN leads on earnings multiple (7.5x) while LFVN leads on capital efficiency (29.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LFVN?

▼

Per LFVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000849146), Lifevantage Corporation (Delaware) generated $228.5M in revenue (+14.2% YoY), $9.8M in net income, and $10.5M in free cash flow against $61.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (80% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.90 (+0.27%)🧬 Cannibal Buyback (-3.20% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 4.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 76/100 (B+) historically ranked in the Top 11% of excess returns over the next 90 days (+7.6% avg 90D alpha vs SPY • 70.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B+

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+8.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LFVN)Realized 20D OHLCV Swing Band: ±7.9%

Deterministic 5-Pillar Attribution (76/100 Composite)

🔍 WHY LFVN SCORES 76/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+19/20 pts (25% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-3.20% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 4.6% FCF Margin ($10.5M FCF) & 80.4% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade A$5.98+0% Next Q

Q2 (-2Q)

Grade A-$5.98-3.7% Next Q

Q3 (-1Q)

Grade A-$5.76+2.1% Next Q

Current

Grade B+$5.88+7.6% Hist 90D α

Trajectory: A (84) → B+ (76)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LFVN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 76/100 (B+) score, LFVN faces multiple-compression risk if 7.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-3.20% YoY Shares) — any gross margin slip below 77.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($6.16) or 200D SMA ($5.89) invalidates the momentum regime and cuts Target Base ($6.36) toward Bear Floor ($4.82).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LFVN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LFVN Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 76%NO 24%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

49.630 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.98>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

8 / 99-Pt Accounting

52-WEEK LASER RANGE25% OF RANGE

L: $4$5.88H: $12

1. Money & Cash Health● HEALTHY

Are profits real cash in the bank?

Real cash coming in backs up reported profits (80% profit margin and healthy balance-sheet cushion).

Factor Grade: B+RQD 16 / 20

2. Big Money & Insiders● BUYING

Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: B-RQD 28 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B+RQD 32 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bullish on LFVN

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (80)

29.2% ROIC with 80.4% gross margin and 14.22% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (80)

Altman-Z 3.98 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BULLISH (73)

28/40 institutional & smart-money positioning score with 16/20 macro alignment.

Bull Case: Why Buyers Like LFVN

✓Strong cash generator (80% profit margin)—profits are backed by real money, not accounting tricks.
✓Company leadership has skin in the game with net positive insider conviction.
✓Clean SEC annual filing review with no major hidden accounting time-bombs.

Bear Case: What Could Go Wrong

!Broader market pullbacks can still drag down strong stocks in the short run.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (LFVN Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LFVN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +14.62%⚡ TESTING RESISTANCE

2026-11-02O $5.84H $6.00L $5.84C $5.88VOL 4.8K

RES: $6.02SUP: $5.08SMA50: $6.16SMA200: $5.89

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LFVN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LFVN Butterfly Map → + Track LFVN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-6.7%/yr Implied 5Y Growth

vs. +14.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LFVN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LFVN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LFVN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LFVN)

Health Care Rank #34 of 1016 ⚔️ MAIA vs LFVN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LFVN vs. MAIA, ACRV, CING, TELO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lifevantage Corporation (Delaware) (LFVN) ranks #34 by composite RQD confidence (76/100, grade B+) and #698 by equity capitalization ($73.9M). Within this direct 5-issuer industry benchmark cohort, LFVN leads on earnings valuation at 7.5x trailing P/E, while LFVN leads on capital efficiency and profitability with 29.2% ROIC and 80.4% gross margin. LFVN currently leads its immediate peer cohort in composite quantitative strength at 76/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LFVN ACTIVE Lifevantage Corporation (Delaware)	B+	76/100	7.5x	80.4%	29.2%	+0.17%	$73.9M	Benchmark Subject
MAIA MAIA Biotechnology Inc.	D	48/100	—	—	-35.0%	-6.78%	$72.9M	/maia-vs-lfvn →
ACRV Acrivon Therapeutics Inc.	D-	38/100	—	—	-35.0%	-5.68%	$75.4M	/acrv-vs-lfvn →
CING Cingulate Inc.	D-	36/100	—	—	-35.0%	-4.05%	$75.5M	/cing-vs-lfvn →
TELO Telomir Pharmaceuticals Inc.	E	34/100	—	—	-35.0%	-3.01%	$71.0M	/telo-vs-lfvn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0000849146

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Lifevantage Corporation (Delaware) (LFVN) reported GAAP revenue of $228.5M (+14.2% vs. FY2024 revenue of $200.2M , and +7.1% cumulative change since FY2023) , GAAP net income of $9.8M, operating cash flow of $11.9M, and free cash flow of $10.5M (+5.6% YoY). On the balance sheet, LFVN closed FY2025 with $61.2M in total assets against $0 in total debt (Altman Z-Score: 3.98, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$228.5M	$9.8M	$11.9M	$10.5M	$61.2M	—
FY2024 (FY)	2024-06-30	$200.2M	$2.9M	$12.2M	$10.0M	$68.5M	—
FY2023 (FY)	2023-06-30	$213.4M	$2.5M	$6.8M	$6.8M	—	—

3. LFVN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LFVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LFVN compare to MAIA and ACRV in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LFVN?

Where is LFVN trading relative to its 50-day, 200-day, and 52-week technical levels?

LFVN last traded at $5.88 (+0.17% on volume of 24,074 shares), positioning the stock -4.55% below its 50-day simple moving average ($6.16) and -0.17% below its 200-day simple moving average ($5.89). Across its 52-week range of $3.90 to $11.71, LFVN sits at the 25.4% percentile with a 14-day RSI of 49.6 (NEUTRAL RANGE) and an implied next-earnings move of ±7.9% ($5.42 to $6.34).

LFVN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell LFVN stock right now?

Lifevantage Corporation (Delaware) (LFVN) currently earns a Roarable Rating of B+ (Buy — BUY) with 76/100 RQD Confidence. High-quality cash engine (80% profit margin, 29% return on capital) with steady institutional support.

What is LFVN's 12-month price target and RQD AI Jury consensus?

LFVN's 12-month base price target is $6.36 (range $4.82 to $12.3), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: LFVN RQD Cockpit LFVN 12M Forecast LFVN Earnings & Move LFVN Dividends & DRIP LFVN Insiders & 13F LFVN Whale Options LFVN Profit Sankey LFVN News & Why

ROARABLE RATING BRIEF • RQD 76/100 (B+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

LFVN — Lifevantage Corporation (Delaware): What the Facts Mean to a Prospective Investor

Engine: roarable-bundle-v1

As of: 2026-11-02T15:08:05Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Lifevantage Corporation (Delaware) (LFVN) carries a composite score of 76 / 100 (B+ — Roarable Buy — Very Good Cash & Smart-Money Inflow).\n- Fundamental Cash Engine (16 / 20): Return on invested capital (ROIC) registers at 29.2% with a free cash flow yield of 14.22% and gross margin of 80.4%.\n- Institutional 13F Whale Flow (9 / 20): Tracks institutional accumulation and dark-pool/options positioning relative to the Biotechnology: Pharmaceutical Preparations cohort.\n- Insider & Congressional Conviction (19 / 20): Evaluates open-market Form 4 executive purchases and Congressional PTR disclosures.\n- Macro Regime Fit (16 / 20): Equity beta of 1.00 across the Health Care sector.\n- Forensic Balance-Sheet Shield (16 / 20): Altman Z-Score of 3.98, Piotroski F-Score of 8/9, and Debt-to-Equity of 0.50.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %	\n	---	---	---	---	---	---	---	---	---	---	\n	$5.87	$73.9M	7.5	6.3	5.5	0.78	2.80%	1.00	$5.12 - $6.41	29.2%

Business & Sector Positioning

Lifevantage Corporation (Delaware) (LFVN) is a NASDAQ-listed Health Care issuer operating in Biotechnology: Pharmaceutical Preparations with a market capitalization of $0.1B.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Operating within Biotechnology: Pharmaceutical Preparations (Health Care), LFVN exhibits an operating margin of 5.3% and net margin of 4.3%. Prospective investors should monitor 2nd-order capex cycles, input cost pass-through in gross margin (80.4%), and valuation discipline (6.3x forward P/E) relative to free cash flow conversion.

Open Questions for Prospective Investors

How sustainable is LFVN's current operating margin (5.3%) and ROIC (29.2%) over the next four quarters?\n2. Does the current valuation multiple (7.5x TTM P/E) adequately discount macro sensitivity (Beta 1.00) in Biotechnology: Pharmaceutical Preparations?\n3. Will upcoming quarterly cash flow conversion support continued balance-sheet strength (Altman Z 3.98)?

LFVN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lifevantage Corporation (Delaware) (LFVN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LFVN Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo • 3d ago

Pro-Dex, Inc. (PDEX) Q1 Earnings and Revenues Surpass Estimates

ProDex (PDEX) delivered earnings and revenue surprises of +37.31% and +0.78%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 3d ago

New LifeVantage Research Explores How Protandim® Nrf2 Supports Cellular Defense Against Five Modern Environmental Toxins*

SALT LAKE CITY, Oct. 29, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN) continues to lead the next generation of healthy aging with its latest in vitro research study examining how five modern environme

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 6d ago

LifeVantage to Announce First Quarter Fiscal Year 2027 Results on November 9, 2026

SALT LAKE CITY, Oct. 26, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today annou

Read Full Source ↗

🟢 CATALYST Yahoo • 14d ago

New Strong Sell Stocks for October 19th

CWH, LFVN and CGAU have been added to the Zacks Rank #5 (Strong Sell) List on October 19, 2026.

Read Full Source ↗

🟢 CATALYST Yahoo • 20d ago

LifeVantage Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SALT LAKE CITY, Oct. 12, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”) today announced that its Board of Directors granted inducement awards to Terrence Moorehead, the C

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 39d ago

LifeVantage Unveils Turnaround Plan to Rebuild Brand, Margins and Growth

Lifevantage (NASDAQ:LFVN) executives outlined a turnaround plan centered on strengthening the company’s brand, improving consumer relevance and increasing operating efficiency during a Water Tower Research conference dis

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 45d ago

LifeVantage to Participate in the WTR Virtual Insights Conference on Wednesday, September 23, 2026

SALT LAKE CITY, Sept. 18, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today an

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 63d ago

LifeVantage (LFVN) Q4 2026 Earnings Call Transcript

Revenue fell 23% as macroeconomic pressures weighed on orders and average order sizes.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LFVN Bull vs. Bear Conversation Board — What's Your Call at $5.88?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LFVN 🐻 33% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $6.93 (+18.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is LFVN (B+ • RQD 76/100) a Buy at $5.87?

Welcome to the LFVN (Lifevantage Corporation (Delaware)) Roar Pit. Current RQD Composite is 76/100 (Roarable Buy — Very Good Cash & Smart-Money Inflow) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (29.2% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $4.87 (-17.0%)

Spot @ $5.87

Pump the brakes on LFVN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on LFVN, but look at what you are paying: 7.5x trailing P/E with 80.4% gross margins. Unless Lifevantage Corporation (Delaware) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $6.75 (+15.0%)

Spot @ $5.87

LFVN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on LFVN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $5.87 (52-wk range $5.12 - $6.41), any beat on forward guidance forces shorts and underweight funds to chase.